Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marissa Termini

Nurse Practitioner, Adult Health Bay Shore, NY Nurse Practitioner

NPI 1154932895 CMS profile 11190328

301 E Main St, Bay Shore, NY 11706

Open in the dashboard

General payments

$6,526

160 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marissa Termini of Bay Shore, NY is reported in the CMS Open Payments database as having received $6,526 across 160 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $525 12
2024 General $365 9
2023 General $1,858 52
2022 General $2,908 62
2021 General $870 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marissa Termini
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Marissa Termini were reported at $525. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Marissa Termini Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $870 $138 $43–$438 $132
2022 $2,908 $165 $54–$494 $149
2023 $1,858 $178 $61–$549 $160
2024 $365 $186 $62–$575 $164
2025 $525 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,237 21 payments
  2. Janssen Pharmaceuticals, Inc $765 15 payments
  3. Medtronic, Inc. $480 14 payments
  4. E.R. Squibb & Sons, L.L.C. $458 8 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $448 9 payments
  6. AstraZeneca Pharmaceuticals LP $436 7 payments
  7. Sanofi-Aventis U.S. LLC $409 9 payments
  8. Novartis Pharmaceuticals Corporation $316 16 payments
  9. Merck Sharp & Dohme Corporation $298 16 payments
  10. Inspire Medical Systems, Inc. $290 1 payment
  11. Other $1,388 44 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,158 149 payments
  2. Travel and Lodging $240 1 payment
  3. Education $128 10 payments
Products named General payments · program years 2021–2025
  1. XARELTO $765 15 payments
  2. CARDIOMEMS $462 6 payments
  3. JARDIANCE $448 9 payments
  4. FARXIGA $420 6 payments
  5. MULTAQ $409 9 payments
  6. VERQUVO $298 16 payments
  7. Inspire Upper Airway Stimulation System $290 1 payment
  8. CAMZYOS $289 4 payments
  9. LifeVest $273 10 payments
  10. Micra $240 1 payment
  11. Other $2,920 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

778

Median for Nurse Practitioner: 389

Drug cost

$209,722

Median for Nurse Practitioner: $21,885

Branded share of claims

26.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 83 $104,227
Xarelto Rivaroxaban Brand 30 $41,754
Entresto Sacubitril/Valsartan Brand 23 $28,789
Multaq Dronedarone Hcl Brand 15 $19,336
Jardiance Empagliflozin Brand 11 $7,619
Metoprolol Succinate Generic 99 $2,109
Rosuvastatin Calcium Generic 67 $943
Atorvastatin Calcium Generic 76 $849
Ezetimibe Generic 15 $635
Bumetanide Generic 13 $519

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

160 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record